Blue Matter Blog

Oncology Trends: Is Past Performance Predictive of Future Returns? – Part II, Unmet Needs & Future Advancements
July 16, 2019

In Part I of this series, we identified and described four key trends in oncology: Novel Drug Targets and Classes of Therapy Novel Drug Designs Tumor Biology-Based Regimens Diagnostic-Driven, Adaptive Regimens: Precision Medicine Despite the significant advances these trends represent, much unmet need remains in oncology. In this installment, we outline some of those key …

Oncology Trends: Is Past Performance Predictive of Future Returns? – Part I, Trends Overview
July 8, 2019

Over the past 5 years, several ground-breaking advancements in oncology have dramatically advanced the standard of care. These include new classes of drugs include the PD(L)1 checkpoint inhibitors, the PARP inhibitors, and the EGFR resistance targeted drugs.  Also included is a general trend towards more precise and targeted treatment decisions, driven by incorporating molecular tests …

Precision Medicine Part III: Co-Evolution of Diagnostics and Pharma Development
April 23, 2019

Better integration of personalized cancer treatments into clinical practice will immensely improve outcomes for patients. But, to achieve the full potential of precision medicine, both pharma and diagnostics must accelerate and broaden their scope of precision medicine beyond their currently limited settings and ensure successful integration into clinical practice. In this installment, we will explore …

Precision Medicine Part II: Current Utility and Challenges in the Clinic
April 8, 2019

Over the past few decades in oncology, targeted therapies—and the tests that identify which tumors will be sensitive to them—have significantly advanced the standard of care in several key settings. However, precision medicine will not achieve its full potential in oncology without broader success in pharmaceutical and diagnostic development, and better integration of both into …

Precision Medicine Part I: The Science Behind Molecular Testing
March 18, 2019

Since scientists first sequenced the human genome nearly 20 years ago, we have all been increasingly enthusiastic about the potential for precision medicine to better diagnose and treat diseases. In oncology, targeted therapies against specific mutations have already demonstrated this promise, though only in the relatively limited settings where these therapies exist and testing is …

Building a Winning Differentiation Strategy in Oncology: Maximizing the End-to-End Stakeholder Experience
March 7, 2019

Part Four in a Series on Oncology Product Commercialization As we’ve written before, oncology launches are occurring more frequently, largely due to a rapidly evolving understanding of disease biology and massive investments in oncology research and development.  As a result, many indications are becoming more complex and competitive, with a greater number of approved molecules …

Helping in the Fight Against Lung Cancer: The Addario Lung Cancer Foundation
February 11, 2019

At Blue Matter, we love what we do.  The work is interesting, and we always feel like we’re learning something new. There’s also a sense that, in our own small way, we’re joining in the fight against some of the world’s worst diseases.  Our team members have a passion for the areas in which they …

Cell-Based Cancer Immunotherapies: Commercial Risk, Curative Reward, Part Two
January 21, 2019

Part Two of a Two-Part Series:  Commercial Opportunity, Challenges, and Outlook In Part One of this series, we provided an overview of how the immune system can fight cancer, as well as the reasons it can sometimes fail in the effort.  In addition, we explored an extremely interesting class of therapies that show great promise …

Cell-Based Cancer Immunotherapies: Commercial Risk, Curative Reward, Part One
January 18, 2019

Part One of a Two-Part Series:  How Cancer Immunity Works & Types of Cell-Based Immunotherapy Until recently, cancer treatments for advanced disease were palliative in nature, seeking to reduce tumor burden and prolong life.  Curing metastatic disease was not considered possible. But over the past few decades, a new class of cancer treatments has demonstrated curative …

The Complex Oncology Audience
December 13, 2018

Part Three in a Six-Part Series on Oncology Product Commercialization In Part One of this series, we outlined five commercial challenges in oncology that biopharma decision-makers must face.  Part Two dealt with the first of those challenges, the “constant state of launch” that now exists in oncology.  In this installment, we introduce the complex array …

We use cookies to provide website functionality and give you the best possible experience. Our Cookie Statement provides more information and explains how to amend your cookie settings.

By pressing the “Accept Cookies” button, the user accepts all Cookies on the Website. View our Cookie Statement.